Relaxin: Review of biology and potential role in treating heart failure

被引：98
作者：
Teichman S.L. [1 ]
Unemori E. [1 ]
Teerlink J.R. [2 ]
Cotter G. [3 ]
Metra M. [4 ]
机构：
[1] Corthera, Inc., Novartis Pharmaceuticals Corp., San Mateo, CA 94402
[2] Section of Cardiology, Veterans Affairs Medical Center, University of California, San Francisco, CA 94121-1545
[3] Momentum Research, Inc., Durham, NC 27707
[4] Section of Cardiovascular Diseases, Department of Experimental and Applied Medicine, University of Brescia, Cardiology, 25123 Brescia
来源：
Current Heart Failure Reports | 2010年 / 7卷 / 2期
关键词：
Acute heart failure; Congestive heart failure; Dyspnea; Pharmacologic therapy; Relaxin; Vasodilation;
D O I：
10.1007/s11897-010-0010-z
中图分类号：
学科分类号：
摘要：
Relaxin is a naturally occurring human peptide initially identified as a reproductive hormone. More recently, relaxin has been shown to play a key role in the maternal hemodynamic and renal adjustments that accommodate pregnancy. An understanding of these physiologic effects has led to the evaluation of relaxin as a pharmacologic agent for the treatment of patients with acute heart failure. Preliminary results have been encouraging. In addition, the other known biologic properties of relaxin, including anti-inflammatory effects, extracellular matrix remodeling effects, and angiogenic and anti-ischemic effects, all may play a role in potential benefits of relaxin therapy. Ongoing, large-scale clinical testing will provide additional insights into the potential role of relaxin in the treatment of heart failure. © The Author(s) 2010.
引用
收藏
页码：75 / 82
页数：7
相关论文
共 55 条
  • [1] Cotter G., Metra M., Milo-Cotter O., Et al., Fluid overload in acute heart failure-re-distribution and other mechanisms beyond fluid accumulation, Eur J Heart Fail, 10, pp. 165-169, (2008)
  • [2] The pathophysiology of acute heart failure-is it all about fluid accumulation?, Am Heart J, 155, pp. 9-18, (2008)
  • [3] Colombo P.C., Onat D., Sabbah H.N., Acute heart failure as "acute endothelitis"-interaction of fluid overload and endothelial dysfunction, Eur J Heart Fail, 10, pp. 170-175, (2008)
  • [4] Hisaw F.L., Experimental relaxation of the pubic ligament of the guinea pig, Proc Soc Exp Biol Med, 23, pp. 661-663, (1926)
  • [5] Fevold H.L., Hisaw F.L., Meyer R.K., The relaxative hormone of the corpus luteum. Its purification and concentration, J Am Chem Soc, 52, pp. 3340-3348, (1930)
  • [6] Jeyabalan A., Shroff S.G., Novak J., Et al., The vascular actions of relaxin, Adv Exp Med Biol, 612, pp. 65-87, (2007)
  • [7] Schrier R.W., Durr J.A., Pregnancy: An overfill or underfill state, Am J Kidney Dis, 9, pp. 284-289, (1987)
  • [8] Baylis C., Relaxin may be the "elusive" renal vasodilatory agent of normal pregnancy, Am J Kidney Dis, 34, pp. 1142-1145, (1999)
  • [9] Dschietzig T., Teichman S.L., Unemori E., Et al., Intravenous recombinant human relaxin in compensated heart failure: A safety, tolerability, and pharmacodynamic trial, J Card Fail, 15, pp. 182-190, (2009)
  • [10] Teerlink J.R.T., Metra M., Felker G.M., Et al., Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF), Lancet, 373, pp. 1429-1439, (2009)
123456